Biotech Values

[genisi]

SGEN' Adcetris is her best bet (assuming CD30 expression). In the relapsed/refractory Hodgkin's trial, patients had 3.5 prior therapies on average and autologous stem cell transplant. ORR was 74% (of that 34% was CR), and median OS was 22.4 months. Since it was approved in Aug, the only way to get the drug here is via private insurance or out of pocket (prior to approval we had a compassionate program but it was shut down with approval). Unfortunately, there are no clinical trials with the drug in Israel either. They refuse to cover it not really because it's so new, rather because the health committee has to vote on every drug and there are quite a few in line with budget problems.